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Abstract
Background: Pancreatic cancer has a high mortality rate because it is usually diagnosed when metastasis have
already occurred (microscopic and gross disease). Ezrin plays important roles in cell motility, invasion and tumor
progression, and it is especially crucial for metastasis. However, its function in pancreatic cancer remains elusive.
Methods and Results: We found that ezrin overexpression promoted cell protrusion, microvillus formation,
anchorage-independent growth, motility and invasion in a pancreatic cancer cell line, MiaPaCa-2, whereas ezrin
silencing resulted in the opposite effects. Ezrin overexpression also increased the number of metastatic foci (6/8 vs.
1/8) in a spontaneous metastasis nude mouse model. Furthermore, ezrin overexpression activated Erk1/2 in
MiaPaCa-2 cells, which might be partially related to the alteration of cell morphology and invasion.
Immunohistochemical analysis showed that ezrin was overexpressed in pancreatic ductal adenocarcinoma (PDAC)
(91.4%) and precancerous lesions, i.e. the tubular complexes in chronic pancreatitis (CP) and pancreatic
intraepithelial neoplasm (PanIN) (85.7% and 97.1%, respectively), compared to normal pancreatic tissues (0%). Ezrin
was also expressed in intercalated ducts adjacent to the adenocarcinoma, which has been considered to be the
origin of ducts and acini, as well as the starting point of pancreatic ductal carcinoma development.
Conclusions: We propose that ezrin might play functional roles in modulating morphology, growth, motility and
invasion of pancreatic cancer cells, and that the Erk1/2 pathway may be involved in these roles. Moreover, ezrin
may participate in the early events of PDAC development and may promote its progression to the advanced stage.
Background
Ezrin, encoded by the Vil2 gene, is a member of the
ERM family; it provides a functional link between the
plasma membrane and the cortical actin cytoskeleton of
the cell. Ezrin plays important roles in cell motility,
morphogenesis, adhesion, survival and apoptosis [1-6]. It
also participates in crucial signal transduction pathways
[7]. Ezrin binds to cell surface glycoproteins, such as
CD43, CD44, ICAM-1 and ICAM-2, through interacting
with their amino (N)-terminal domains. Ezrin also binds
to filamentous actin through its carboxyl (C)-terminal
domains [8]. Ezrin has been linked to molecules that
control the phosphatidylinositol-3-kinase, AKT, Erk1/2
MAPK and Rho pathways, which are functionally
involved in signaling events regulating cell survival, pro-
liferation and migration. Phosphorylation of ezrin
induces its translocation from the cytoplasm to the
plasma membranes of microvillus and confers the ability
of binding to plasma membrane and actin filaments
[9-12].
Ezrin is expressed in a variety of normal and neoplas-
tic cells, including many types of epithelial, lymphoid
and glial cells [5,13,14]. In melanoma cells, ezrin has
been shown to be localized in phagocytic vacuoles, sug-
gesting that its association with the actin cytoskeleton is
crucial for the phagocytic activity [15]. Phagocytic beha-
vior is usually considered to be an indicator of high-
grade malignancy in melanomas. In addition, immuno-
histochemical analysis has demonstrated a significant
correlation between increased ezrin immunoreactivity
and a high histological grade in astrocytoma [16]. In a
complementary DNA (cDNA) microarray analysis of
highly and poorly metastatic rhabdomyosarcomas, ezrin
was indicated to be a key regulator of metastasis [17].
Ezrin overexpression has also been considered as an
independent predictor of adverse outcome of
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gastrointestinal stromal tumors [18]. These results indi-
cated that ezrin expression level is closely associated
with malignant progression of cancer.
Consistent with these reports, suppression of ezrin pro-
tein expression and disruption of its function significantly
reduced lung metastasis in a mouse osteosarcoma model
[19]. Furthermore, high-level ezrin expression in canine
osteosarcomas has been associated with early develop-
ment of metastasis [20]. Ezrin silencing by small hairpin
RNA could reverse the metastatic behavior of human
breast cancer cells [21]. Taken together, the observed
effects of ezrin overexpression and silencing on the cell
malignant transformation indicate a role for ezrin in reg-
ulating tumor metastasis and progression [22].
In pancreatic carcinomas, a high-level ezrin expression
is associated with high metastatic potential; membrane
translocation of ezrin might play a role in the progres-
sion from borderline tumor to malignant transforma-
tion. Patients with pancreatic ductal adenocarcinoma
(PDAC) with membranous ezrin expression exhibited
poorer prognosis compared to those without membra-
nous ezrin expression, and ERM protein was more likely
to be present in poorly differentiated cancers [23-26]. A
recent study showed that overexpression of pEzrin
(Tyr353) in pancreatic cancers was associated with posi-
tive lymph node metastasis, less differentiation, pAkt
overexpression and shorter survival times [27]. Ezrin
can interact with cortactin to form podosomal rosettes
in pancreatic cancer cells, thereby playing a role in pan-
creatic cancer invasion [28]. However, the mechanisms
of ezrin-mediated tumor development still require
further elucidation. In this study, we investigated the
effect of ezrin on the motility and invasion ability of the
pancreatic cancer cell line MiaPaCa-2, as well as the
expression of ezrin in pancreatic duct adenocarcinoma,
chronic pancreatitis and normal pancreatic tissues.
Materials and methods
Antibodies and plasmids
Rabbit polyclonal anti-ezrin antibody was purchased
from Upstate technology (Lake Placid, NY). Rabbit poly-
clonal anti-phosphorylated Ezrin (Tyr353), mouse
monoclonal anti-AKT, anti-phospho-AKT (Ser473),
anti-p44/42 MAPK (Erk1/2) and anti-phospho-p44/42
MAPK (Erk1/2) (Thr202/Tyr204) antibodies were pur-
chased from Cell Signaling Technology (Beverly, MA,
USA). The mouse monoclonal antibody VSV-G (P5D4)
was purchased from Roche Applied Science (Indianapo-
lis, USA). The mouse monoclonal antibody GAPDH was
purchased from Santa Cruz Biotechnology (Santa Cruz,
CA). The secondary antibodies, including the rhoda-
mine-conjugated goat anti-mouse, FITC-conjugated goat
anti-mouse, horseradish peroxidase-conjugated anti-
mouse and anti-rabbit antibodies, were purchased from
ZhongShan Biotechnology (Beijing, China). The pcb6
vector that contains the cDNA encoding VSV-G-tagged
ezrin was kindly provided by Dr. Monique Arpin [14].
Plasmid-based silencing of ezrin expression
The mammalian expression vector, pSilencer 2.1-U6
(Ambion, Austin, Texas, USA) was used for expressing
of siRNA in MiaPaCa-2 cells. Briefly, two primer pairs
were synthesized, with the first pair encoding the
nucleotides, GGGCCAAGTTCTACCCTGAAG (376-
396, No. 1) followed by a 9 base “loop”, TTCAAGAGA
and an inverted repeat and the second pair encoding the
nucleotides, GGCTTTCCTTGGAGTGAAA (849-867,
No. 2) followed by the loop and the inverted repeat. A
nonspecific 21-nucleotide siRNA scrambled to the first
pair, GACCGAGTCCGAAGTCAGCT (No. 3) was used
as a control. The primer pairs were annealed and
inserted into the BamH I and Hind III sites of pSilencer
2.1-U6 and transformed into JM109 competent cells
(Promega, Madison, WI, USA). Positive clones were
identified and verified by restriction enzyme analysis
and sequence analysis.
Cell culture and cell transfection
The pancreatic adenocarcinoma cell line MiaPaCa-2
(American Type Culture Collection, Manassas, Virginia,
USA) was grown in DMEM (GIBCO, Grand Island,
New Yolk, USA) supplemented with 10% fetal calf
serum (FCS) and 1% L-glutamine (Invitrogen, Karlsruhe,
Germany) and maintained at 37°C in 5% CO2. All trans-
fections reactions were performed using Lipofectamine
2000 (Invitrogen; Carlsbad, CA) in accordance with the
manufacturer’s instructions. Stable transfectants were
selected with 800 μg/mL G418 (Sigma-Aldrich, St.
Louis, MO, USA), and individual clones were isolated.
Scanning electron microscopy
Cells were cultured on coverslips and harvested after 24
hours. Cells were then washed with phosphate buffered
saline (PBS) and fixed with 2.5% glutaraldehyde at 4°C
for 12 hours. After thoroughly washing with PBS, the
fixed cells were dehydrated through an ethanol series
and dried at room temperature. The samples were
coated with a thin film of silver and examined under a
scanning electron microscope (JEOL/JSM-6000F, JEOL
Ltd., Tokyo, Japan).
Western blotting
Cell lysates (30 μg protein) resolved on 10% SDS-PAGE
were transferred to a polyvinylidene difluoride mem-
brane (Millipore, Bedford, MA). For immunoblotting,
we used antibodies against ezrin, VSV-G, phospho-ezrin
(Tyr353), phospho-p44/42 MAPK(Erk1/2) (Thr202/
Tyr204), p44/42 MAPK (Erk1/2), phospho-AKT
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(Ser473), AKT and GAPDH. The immunoreactive
proteins were visualized using the ECL western blotting
system (Amersham International, little Chalfont, UK),
and densitometric analysis was performed using the
Image Pro-Plus Software.
Indirect immunofluorescence
Cells were plated on glass coverslips for 24 hours, fixed
with 3.7% paraformaldehyde for 20 minutes and then
permeabilized with PBS containing 0.05% Triton X-100
for 10 minutes. The cells were then blocked with 1%
BSA in PBS for 1 hour, followed by adding of primary
antibodies diluted in blocking buffer at 4°C overnight at
the following concentrations: anti-ezrin (serum was
diluted 1:150) and anti-VSV-G (serum was diluted 1:75).
Subsequently, the cells were washed with PBS and then
incubated for 1 hour in either the goat-anti-mouse IgG
TRITC-conjugated antibodies or the goat-anti-rabbit
IgG FITC-conjugated antibody, both of which were
diluted in the blocking buffer (1:60). Afterwards, 4’,6-
diamidino-2-phenylindole (DAPI) was used for nuclear
counter-staining. Finally, the cells were mounted in the
fluorescent mounting medium (Applygen Technologies
Inc., Beijing, China) and viewed with under a fluores-
cence microscope (BH2-RFCA; Olympus Optical Co.,
Ltd, Tokyo, Japan).
Cell growth assay and flow cytometry analysis
In vitro cell growth was assessed using the Dojindo Cell
Counting Kit-8 (Dojindo Laboratory, Kumamoto, Japan)
according to the supplier’s recommendations. Clones
were plated in tissue culture plates at a density of 1 ×
103 cells in 0.1 mL of culture medium per well and
grown in DMEM with 10% FCS in 5% CO2 at 37°C. The
number of cells per well was quantified by daily mea-
surement of the absorbance at 450 nm for 7 days after
plating. All experiments were performed in triplicate on
three separate occasions. Replicate growth curves were
plotted for each of the clones and compared to control
cells grown under identical culture conditions. To deter-
mine the cell cycle distribution, 5 × 105 cells were plated
in 60-mm dishes and cultured for periods of up to 2
days. The cells were then collected by trypsinization,
fixed with 70% ethanol, washed with PBS, resuspended
in 1 mL of 0.01 M PBS with RNase and 50 μg/mL pro-
pidium iodide, incubated for 20 minutes in the dark at
room temperature and analyzed by flow cytometry using
a FACS Calibur (Becton Dickinson, Bedford, MA).
Colony formation assay
An equal amount of 1% Noble agar solution pre-
warmed to 40°C was added to DMEM containing 20%
FCS pre-warmed to 37°C to make a 0.5% agar solution.
After rapid mixing by inversion, the resultant solution
was added to 24-well plates (0.5 mL/well). After reach-
ing 70 to 80% confluence, the cells were trypsinized,
washed with D-Hanks three times and diluted in Noble
agar solution (0.35% Noble agar in DMEM with 10%
FCS) at 37°C. The cell suspensions were then added
into 24-well plate with a 0.5% agar layer (200 cells in
0.5 mL) (three wells per condition). The plates were
incubated at 37°C with 5% CO2 for three weeks. The
colony formation ability under each condition was
assessed using untreated cells as control.
Transfilter migration and invasion assays
Transfilter assays were performed with 8.0-μm pore
inserts in 24-well BioCoat Chambers (Becton Dickinson)
using 5 × 104 cells in serum-free DMEM. The DMEM
medium with 10% FCS was placed in the lower cham-
bers as a chemoattractant. For invasion assays, Matrigel-
coated transwell chambers were used. For migration and
invasion assays, the cells were removed from the upper
surface of the filter by scraping with a cotton swab after
12 and 24 hours in culture respectively. Migrated cells
and invasive cells were fixed and stained with the crystal
violet reagent. Mean values of the data obtained from
three separate chambers were presented.
Tumor transplantation and spontaneous/experimental
metastasis
Female BALB/c nude mice (body weight, 15 to 17 g)
were bred under specified pathogen-free conditions
(26°C, 70% relative humidity and a 12-h light/12-h
dark cycle) in a germ-free environment with free
access to food and water. To examine the effects of
ezrin on tumor cell proliferation and metastasis
in vivo, Mia ez22-B, Mia pcb6, Mia ezsi-scram and
Mia ezsi-E (5 × 106 cells/100 μL normal sodium/
mouse) were used. For spontaneous metastasis, the
cells were injected into the inferior of pancreas capsule
of the nude mice, whereas for experimental metastasis,
the cells were injected into the tail vein of the nude
mice. The mice were monitored every 2 to 3 days and
sacrificed 10 weeks after injection. Tumors were
excised, and metastasis in the lung, viscera, liver,
draining lymph nodes and other organs were assessed.
These tumors were embedded into paraffin. Histologi-
cal analysis of the tissue sections stained with hema-
toxylin and eosin were performed to confirm the
presence of metastasis in the various organs. Based on
the gross and histological analyses, animals were
assessed as positive or negative with respect to metas-
tasis. Animal handling and experimental procedures
were approved by the Peking Union Medical College
Hospital animal experiments committee. It was also in
accordance with the recommendations by the regional
and country animal ethics committee.
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Patients, specimens and immunohistochemistry
This study was approved by the Institutional Review
Board of Peking Union Medical College Hospital, Chi-
nese Academy of Medical Sciences (CAMS) and Peking
Union Medical College (PUMC). Surgically resected spe-
cimens from 70 patients (age range, 29 to 78 years) with
PDAC were examined. This patient population repre-
sented a randomly selected subgroup from a clinical ser-
ies including all patients who underwent surgical
resection between June 1998 and December 2005 in the
Department of Surgery at Peking Union Medical College
Hospital. The diagnosis of PDAC, histological grading
and pathologic staging were re-evaluated and/or con-
firmed by two independent pathologists. PanIN lesions
(n = 34) and CP (n = 28) were assessed and graded in
the pancreatic tissues adjacent to the tumor in hemato-
xylin and eosin-stained slides.
Immunostaining for ezrin was performed using the
primary rabbit polyclonal antibody against human ezrin
(diluted 1:150) at 4°C overnight after antigen retrieval in
10 mM sodium citrate buffer (pH 6.0) for 15 minutes at
95°C, followed by incubation with an HRP-labeled anti-
rabbit antibody for 1 hour. Immunostaining and clinico-
pathologic features were evaluated microscopically by
two pathologists. Ezrin-specific immunoreactivity was
scored by estimating the percentage of labeled tumor
cells as follows: score 0, < 25% positive cancer cells;
score +, 25-50% positive cancer cells; score ++, 50-75%
positive cancer cells; and score +++, > 75% positive can-
cer cells. Specimens were considered positive for ezrin
expression when the scores were + to +++ and were
considered negative for ezrin expression when the score
was 0. Pictures were collected using the MicroView
MVC2000 image apparatus and software.
Statistical analysis
Each experiment was performed three to four times. All
of the data were expressed as mean ± SD. Statistical
analysis was performed using the Microsoft Excel soft-
ware package. Comparisons between groups were con-
ducted using Welch’s t test. Correlation of ezrin
immunoreactivity with clinicopathologic parameters
were analyzed by Fisher’s exact test. Differences were
considered statistically significant at P < 0.05.
Results
Establishment of ezrin overexpression monoclones and
silencing of the ezrin gene in MiaPaCa-2 cells
To study the function of the Vil2 gene in MiaPaCa-2
cells, the pcb6-ezrin-VSV-G vector was adopted to stably
overexpress the ezrin protein, and the pcb6 vector was
used as a control. For ezrin silencing, the three ezrin siR-
NAs, described in the Materials and methods, were
synthesized and transfected into MiaPaCa-2 cells.
Western blot analysis showed the No. 2 siRNA inhibited
ezrin more efficiently (data not shown). Thus, the No. 2
and No. 3 siRNA sequences were cloned into the pSilen-
cer 2.1 U6 vector. G418-screened MiaPaCa-2 cells were
used for analysis, and the stable cell clones Mia ez22-B,
Mia pcb6, Mia ezsi-B, Mia ezsi-E and Mia ezsi-scram
were selected. Western blot analysis showed that ezrin
protein expression was efficiently increased by 3.8 folds
in the Mia ez22-B cells compared to the Mia pcb6 cells
(Figure 1A, B). It was also shown that ezrin protein
expression was efficiently decreased by 70.5% and 90.1%
in the Mia ezsi-B and Mia ezsi-E cells, respectively, com-
pared to that in the Mia ezsi-scram cells (Figure 1C). In
addition, immunoflurescence staining using the VSV-G-
tagged ezrin antibody further confirmed its stable overex-
pression in the MiaPaCa-2 cells (Figure 1D, E), which
also showed that ezrin protein expression was dramati-
cally decreased in the Mia ezsi-E cells (Figure 1G)
compared to that in the Mia ezsi-scam cells (Figure 1F).
Ezrin overexpression enhancing the formation of cell
protrusions and cell microvilli
To explore whether ezrin is involved in cytoskeleton
modulation, we studied the morphological changes of the
stable transfectants by scanning electron microscopy
(SEM). Compared to those in the Mia pcb6 cells, there
was a sharp increase in the numbers of membrane pro-
trusions and more elongated membrane projections in
the Mia ez22-B cells (Figure 2B). The Mia pcb6 cells
exhibited a smooth edge and fewer projections (Figure
2A). In contrast, compared to those in the Mia ezsi-
scram cells, a dramatic decrease in the numbers of mem-
brane protrusions and smooth edges were observed in
the Mia ezsi-E cells (Figure 2D), and the Mia ezsi-scram
cells showed more projections and more elongated mem-
brane projections (Figure 2C). The morphologic changes
suggest possible alteration of tumor cell behavior.
Ezrin altering anchorage-independent growth ability
without affecting cell proliferation or cell cycle
distribution in vitro
A series of experiments were conducted to determine the
effect of different ezrin protein levels on the proliferation
of MiaPaCa-2 cells in vitro. The effect of the ezrin protein
on cell growth rate was examined by the CCK-8 assay.
The change in the ezrin protein level had no significant
effect on the cell growth rate in vitro (Figure 3A). The
flow cytometry assay further showed that changes in the
ezrin protein level did not affect the cell cycle distribution
(Figure 3B). To further characterize the effect of ezrin on
anchorage-independent growth ability, the colony forming
assay was performed. Ezrin overexpression facilitated the
anchorage-independent growth ability of the Mia ez22-B
cells when compared to that of the Mia pcb6 cells, and
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ezrin silencing decreased the anchorage-independent
growth ability in the Mia ezsi-E cells compared to that of
the Mia ezsi-scram cells (Figure 3C). Statistical analysis
showed that the anchorage-independent growth ability of
the tumor cells in soft agar was increased by 103.1% in the
Mia ez22-B cells compared to that in the Mia pcb6 cells,
and it was decreased by 54.3% in the Mia ezsi-E cells com-
pared to that in the Mia ezsi-scram cells (Figure 3D).
These results indicated that ezrin could enhance the
anchorage-independent growth ability of MiaPaCa-2 cells.
Ezrin increasing the cell motility and invasion ability of
MiaPaCa-2 cells
Cell motility ability was examined by determining of the
migration rate through a polyethylene filter in the
absence of Matrigel. The migration rate of the Mia
ez22-B cells (Figure 4b) was greatly increased compared
to that of the Mia pcb6 cells (Figure 4a). The average
cell number of the Mia ez22-B cells migrating to the
lower chamber was 105 ± 5.06 per high-power field
(0.312 mm2/HPF), compared to 40.4 ± 2.86/HPF of the
Mia pcb6 cells. The quantitative analysis showed that
cell migration to the lower chamber was increased by
1.59 folds in the Mia ez22-B cells compared to that in
the Mia pcb6 cells (P < 0.01) (Figure 4c). Compared to
that of the Mia ezsi-scram cells (Figure 4d), the migra-
tion rate of the Mia ezsi-E cells (Figure 4e) was greatly
decreased. The average cell number of the Mia ezsi-E
migrating to the lower chamber was 5.39 ± 0.32/HPF,
compared to 36.7 ± 1.453/HPF of the Mia ezsi-scram
cells. The quantitative analysis showed that cell migra-
tion to the lower chamber were decreased by 58.3% in
the Mia ezsi-E cells compared to that in the Mia ezsi-
scram cells (P = 0.00003) (Figure 4f).
Figure 1 Stable overexpression and silencing of ezrin in MiaPaCa-2 cells. (A) Western blot showed the ezrin protein was overexpressed in
the Mia ez22-B cells compared to the Mia pcb6 cells using an ezrin antibody. The relative ezrin protein level was quantified by densitometry
analysis. The ezrin protein was efficiently increased by 3.8 folds in the Mia ez22-B cells. (B) Ectopic expression of ezrin in the Mia ez22-B cells was
detected using a VSV-G antibody (VSV-G tag in the pcb6-ezrin vector). (C) The expression level of ezrin protein was dramatically decreased by
70.5% and 90.1% in the Mia ezsi-B and the Mia ezsi-E cells, respectively, compared to that in the Mia ezsi-scram cells. GAPDH was used as a
loading control. (D) The Mia pcb6 cells were stained with the ezrin antibody and a FITC-conjugated second antibody to detect the ezrin protein
expression. (E) The vector tag VSV-G antibody and a Rhodamine-conjugated second antibody were used to detect the exogenous ezrin protein
expression. (F, G) The Mia ezsi-scram and the Mia ezsi-E cells were stained with the ezrin antibody and the FITC-conjugated second antibody to
detect the ezrin protein expression.
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We next examined whether ezrin can affect the inva-
sion activity of pancreatic cancer cells by the Matrigel
invasion assay. Cell invasive activity was also dramati-
cally enhanced in the Mia ez22-B cells (Figure 5b) com-
pared to that in the Mia Pcb6 cells (Figure 5a). The
average cell number invading to the lower chamber for
24 hours was 314 ± 46.93/HPF in the Mia ez22-B cells,
compared to 144 ± 20.42/HPF in the Mia pcb6 cells.
The quantitative analysis demonstrated that the number
of the Mia ez22-B cells invading to the lower chamber
was increased by 1.18 folds compared to that of the Mia
pcb6 cells (P = 0.0045) (Figure 5c). In addition, cell
invasive activity was also dramatically decreased in the
Mia ezsi-E cells (Figure 5e) compared to that in the Mia
ezsi-scram cells (Figure 5d), which was 20.6 ± 4.06/HPF
and 158 ± 17.85/HPF, respectively. The quantitative
analysis showed that the number of Mia ezsi-E cells
invading to the lower chamber was decreased by 87.0%
compared to that of the Mia ezsi-scram cells (P =
0.0017) (Figure 5f). Both the increase and decrease of
cell motility and invasion might result from morphologi-
cal alterations of the MiaPaCa-2 cells, such as increased
protrusions and microvilli.
Ezrin overexpression inducing Erk1/2 activation
The results described above indicate that ezrin is
involved in the motility and invasion of MiaPaCa-2 cells.
Erk1/2 signaling has been shown to disrupt actin stress
fibers, which in turn increases cell motility by changing
actin dynamics and decreasing of cell adhesion [29]. The
PI3-kinase pathway has also been shown to be responsi-
ble for RAC-dependent membrane ruffling downstream
of the Ras signaling pathway [30]. It has been recently
reported that phosphorylation of ezrin is required for
metastatic behavior of tumor cells [31]. Our results
showed that ezrin overexpression increased the level of
phosphorylated-Erk1/2 protein without altering the level
of total Erk1/2 in MiaPaCa-2 cells. However, there was
no obvious alteration in the level of phosphorylated-
Erk1/2 protein in the Mia ezsi-E cells. Those results
suggest that the Erk1/2 pathway might participate in the
ezrin-mediated cell growth, motility and invasion. More-
over, there were no obvious changes in the protein
levels of Akt, phosphorylated-Akt and phosphorylated-
ezrin (Tyr353) in both the ezrin silencing and the ezrin
overexpression clones of MiaPaCa-2 cells (Figure 6).
Ezrin overexpression promoting metastasis of MiaPaCa-2
cells in vivo
Tumorigenicity and metastasis of the Mia ez22-B, Mia
pcb6, Mia ezsi-E and Mia ezsi-scram cells were com-
pared in xenograft models. Spontaneous and experimen-
tal metastasis in mouse models were examined to study
the role of ezrin in the growth and metastasis of Mia-
PaCa-2 cells in vivo. In the spontaneous metastasis
models, the tumor incidences were 100% (8/8) in the
Figure 2 Scanning electron microscopy showed increased formation of membrane protrusions and microvilli in the Mia ez22-B cells
(B) compared to that in the Mia pcb6 cells (A). A sharp decrease of the membrane protrusions and smooth edge in the Mia ezsi-E cells (D)
compared to those in the Mia ezsi-scram cells (C).
Meng et al. Journal of Translational Medicine 2010, 8:61
http://www.translational-medicine.com/content/8/1/61
Page 6 of 14
Mia ez22-B, Mia pcb6, Mia ezsi-E and Mia ezsi-scram
cell-treated animals. The body and tumor weight of the
experimental animals showed no apparent differences
among the four cell clone-treated animals (P > 0.05)
(Table 1). Six out of the eight nude mice treated with
the Mia ez22-B cells developed mesentery lymph node
metastasis, whereas only one out of the eight Mia pcb6-
treated mice developed mesentery lymph node metasta-
sis (P < 0.05). In addition, one out of the eight Mia
ez22-B-treated mice displayed a diaphragm metastasis.
Moreover, one out of the eight Mia ezsi-scram-treated
mice developed mesentery lymph node metastasis,
whereas no metastasis was found in the Mia ezsi-E-trea-
ted animals (P > 0.05); none of the four groups was
found to be present with internal organ metastasis
(Table 1). In the experimental metastasis mouse models,
two out of the eight Mia ez22-B-treated mice exhibited
tumor metastasis, with one metastasis found in the
spinal cord and the other in the pelvic cavity and adre-
nal gland area. No metastasis was found in the nude
mice treated with the other three cell lines (P > 0.05).
These data indicate that ezrin overexpression can induce
metastasis in vivo in spontaneous metastasis mice mod-
els; however, ezrin silencing had no obvious effect on
the metastatic potential of MiaPaCa-2 cells.
Immunohistochemical analysis of ezrin expression in
pancreatic ductal carcinoma samples
To study the role of ezrin in pancreatic cancer, we ana-
lyzed its expression pattern in 70 PDAC patients and 61
normal pancreatic or paraneoplastic tissues (more than
1.5 cm away from the tumor). Ezrin was not detectable
in normal pancreatic ducts and acini (Figure 7A); how-
ever, 64 PDAC samples were found to be ezrin positive
(91.4%, 64/70) (Figure 7B-D, Table 2), suggesting that
ezrin was overexpressed in human PDAC and that ezrin
expression was likely associated with pancreatic cancer
development. To determine whether or not ezrin
expression was correlated with any clinical-pathological
parameters, the relationship between ezrin expression
and histological grading, as well as clinical staging was
analyzed. We found that ezrin expression was not corre-
lated with histological grading, pathologic stage, lymph
node status or the depth of invasion (Table 2).
Figure 3 Effects of ezrin on MiaPaCa-2 cell growth and anchorage-independent growth. (A) The cell growth curves of the Mia ezsi-scram,
Mia ezsi-E, Mia pcb6 and Mia ez22-B cells were assayed on days 1-7. (B) Flow cytometry assay showing the percentage of different cell cycle
phases in the four cell clones. (C) Anchorage-independent growth assay of ezrin-overexpressing and ezrin-silencing cells. The cell growth ability
in soft agar of the four cell clones was examined for three weeks. Columns, mean; bars, SD. (D) Statistical analysis of colony formation in the four
cell clones. There was a significant difference of the colony formation ability between the Mia ez22-B and the Mia pcb6 cells, as well as between
the Mia ezsi-scram and the Mia ezsi-E cells, respectively, shown by x2-test. The results are expressed as the mean ± SD of three independent
experiments.
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Figure 4 Effects of ezrin on cell motility in vitro. BioCoat Chambers were used to detect cell migration and representative fields were
photographed. Black-arrows indicate the 8-µm membrane pores, and hollow-arrows indicate cells that had migrated through the membrane,
which were stained with Crystal Violet (a). Cell migration of the Mia ez22 (b), Mia pcb6 (a), Mia ezsi-E (e) and Mia ezsi-cram (d) cells after 12
hours were shown. The cells migrating to the lower chambers were analyzed. For quantification, the cells were counted in 10 random fields
under a light microscope (×400). Compared to the Mia pcb6 cells, the Mia ez22-B cells showed a significant increase in migration by x2-test (c).
The decrease in the numbers of migrated cells in the Mia ezsi-E cells compared to those of the Mia ezsi-scram cells was statistically significant,
shown by the x2-test (f). Columns: mean; bars: SD.
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Figure 5 Effects of ezrin on cell invasion in vitro. Matrigel-coated transwell chambers were used to detect cell invasion and representative
fields were photographed. Cell invasion of the Mia ez22 (b), Mia pcb6 (a), Mia ezsi-E (e) and Mia ezsi-cram (d) cells after 24 hours were shown.
The cells invading to the lower chambers were analyzed. Compared to the Mia pcb6 cells, the Mia ez22-B cells showed a significant increase in
invasion by x2-test (c). The decrease in the numbers of invasive cells in the Mia ezsi-E cells compared to those of the Mia ezsi-scram cells was
statistically significant, shown by the x2-test (f). Columns: mean; bars: SD.
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Ezrin expression in the tubular complexes in CP and
PanIN, as well as in the proliferated intercalated ducts in
the pancreatic tissue adjacent to PDAC
We then investigated the role of ezrin in precancerous
lesions, including the tubular complexes in CP and
PanIN that are considered to be precancerous lesions of
PDAC. In total, 24 out of 28 (85.7%) samples displayed
positive staining of ezrin in the tubular complexes (duc-
tal-like cells, Figure 8E). 33 out of 34 PanIN cases
(97.1%) were ezrin positive (Figure 8B-D). As previously
reported, PanIN can be classified into three main stages
(1, 2 and 3) based on hyperplasia status and morphology
of the epithelial cells. In this study, 9 PanIN-1, 13
PanIN-2 and 12 PanIN-3 samples were examined. Ezrin
expression was observed in 8/9 (88.9%) of the PanIN-1
cases, 13/13 (100%) of PanIN-2 and 12/12 (100%) of
PanIN-3 (Figure 8B-D). No significant differences in
ezrin-positive staining were found among the three
classes of PanIN lesions (P > 0.05). We also observed
that ezrin was expressed in the intercalated duct cells
(Figure 8A) in pancreatic tissue adjacent to the adeno-
carcinoma. These results indicate that ezrin expression
is associated with early stages of pancreatic cancer
development.
Discussion
Ezrin is the best characterized member in the ERM
family; it shares the common membrane-binding N-
terminal FERM domain with band-4.1 family members
[32]. Ezrin linking the cell membrane to actin cytoskele-
ton allows a cell to interact with its microenvironment
and provides an “intracellular scaffolding” that facilitates
signal transduction through a number of growth factor
receptors and adhesion molecules [2,11,33]. Positioned
at the cell membrane-cytoskeleton interface, ezrin may
be a nexus in the metastatic phenotype, playing a cen-
tral, necessary and early role in the process of metastasis
[22]. Upon threonine and tyrosine phosphorylation,
ezrin assumes an active, “open” conformation and, in
turn, moves to the cell membrane and directly or indir-
ectly tethers F-actin to the cell membrane. Ezrin resides
at the nexus of multiple pathways regulating cellular
behavior that can influence metastatic potential, includ-
ing cell survival, motility, invasion and adherence. Ezrin
participates in several crucial signal transduction path-
ways, including the MAPK, AKT, Rho kinase and CD44
pathways, promoting cytoskeletal reorganization and
subsequent morphogenetic alterations [3,5,8,11]. High-
level ezrin expression was observed in many tumor cell
lines, such as breast carcinoma and rhabdomyosarcoma
cell lines [19-21]. Ezrin overexpression was also been
observed in borderline lesions and pancreatic cancer tis-
sues and associated with tumor malignant transforma-
tion and metastatic potential [23-26]; however, its role
and mechanisms remain elusive.
The invasion of cells into the surrounding tissue is a
multi-step action that requires cell-cell contact, cell
motility and degradation of the extracellular matrix by
matrix metalloproteinases [34,35]. Here we demon-
strated that ezrin was involved in the cytoskeleton mod-
ulation by SEM, showing the ezrin-induced changes in
cell protrusions, cell microvilli and pseudopodia
Figure 6 Ezrin overexpression increasing the level of
phosphorylated Erk1/2 in MiaPaCa-2 cells. The levels of
phosphorylated-ezrin, total AKT, phosphorylated-AKT, total Erk1/2
and phosphorylated Erk1/2 were determined by western blot in the
Mia ezsi-scram, Mia ezsi-E, Mia pcb6 and Mia ez22-B cells. GAPDH
was used as a loading control.
Table 1 Ezrin induces enhanced tumor metastasis in vivo
groups body weight (g) tumor weight(g) tumor incidence metastasis
average range average range MLN Dia IO
Mia pcb6 18.14 13.9-20.7 3.08 1.55-4.95 8/8 1/8 0/8 0/8
Mia ez22-B 20.94 15.7-24.2 3.84 1.17-5.80 8/8 6/8* 1/8 0/8
Mia ezsi-scram 18.35 13.5-21.3 3.22 2.50-5.25 8/8 1/8 0/8 0/8
Mia ezsi-E 18.84 14.0-25.0 3.02 2.30-4.23 8/8 0/8 0/8 0/8
MLN: mesentery lymphoid nodes Dia: diaphragm IO: internal organs
* Statistically different (P < 0.05)
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compared to the control cells. Consistent with these
results, the chamber migration and invasion assays con-
firmed that ezrin expression could alter the cell migra-
tion and invasion abilities of pancreatic cancer cells.
Ezrin is a cytoskeletal protein that might affect the
assembly of cytoskeletal elements at the cytoplasmic
face of the membrane and the nuclear skeleton, which
would then facilitate cell migration and invasion. These
results were in agreement with the previous reports
demonstrating that changes in cytoskeleton might be a
key factor in regulating neoplastic progression and
tumor growth [13,22,32,36].
Our results showed that increased level of the ezrin
protein was correlated with an increase in anchorage-
independent growth of tumor cells, consistent with the
previous finding in glioma cells [13]. We also established
experimental and spontaneous mice models and showed
that ezrin overexpression could enhance tumor metasta-
sis in vivo, consistent with our observations in the cell
motility/invasion and soft agar colony formation assays
in vitro.
Our results also showed that ezrin overexpression
could induce metastasis in vivo in the spontaneous
metastasis mouse model; however, ezrin silencing
exerted no obvious effect on the metastatic potential of
MiaPaCa-2 cells. These observations might be explained
by the fact that MiaPaCa-2 cells is a cell line with low
metastatic potential; therefore, the effect of ezrin silen-
cing on metastasis may not be obvious. In addition,
ezrin silencing might affect other signal pathway.
A striking feature of ezrin overexpression was the
increased formation of surface protrusions that play
essential roles in cell motility [37]. Aside from the
increased formation of protrusions, we proposed another
possible mechanism for the effects of ezrin on cell inva-
sion. Our results showed that phosphorylated Erk1/2 was
markedly increased in the Mia ez22-B cells, although no
significant changes were observed in the Mia ezsi-E cells
compared to the controls. Activation of Erk1/2 by ezrin
in MiaPaCa-2 cells indicates that the Erk1/2 MAPK path-
way is one of the mediators of ezrin signaling. Therefore,
the Erk1/2 pathway may also be involved in ezrin-
induced cell motility, invasion and morphological
changes in pancreatic ductal adenocarcinoma. This result
is consistent with previous studies showing that the
Erk1/2 pathway is involved in the reappearance of the
actin cytoskeleton, allowing for the extension of ruffles
into the active protrusions that are required for cell moti-
lity and, therefore contributing to the alteration of cell
motility and invasion [29,30]. Although the phosphatidy-
linositol 3-kinase/Akt pathway is involved in ezrin-
mediated cell survival [11], we did not find corresponding
Figure 7 Ezrin expression in normal pancreatic tissue and pancreatic ductal adenocarcinoma shown by immunohistochemistry. (A)
Normal pancreatic tissue. (B) Well-differentiated pancreatic ductal adenocarcinoma. (C) Moderate-differentiated pancreatic ductal
adenocarcinoma. (D) Poor-differentiated pancreatic ductal adenocarcinoma.
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evidence in either the ezrin-overexpressing or the ezrin-
silencing MiaPaCa-2 cells. Although a recent study has
shown that overexpression of pEzrin(Tyr353) in pancrea-
tic cancers is associated with positive lymph node metas-
tasis, less differentiation, pAkt overexpression, and
shorter survival times [27], we did not observe any
change of ezrin phosphorylation in either the ezrin over-
expressing or the ezrin silencing MiaPaCa-2 cells. There-
fore, phosphorylation of ezrin may not affect the motility
and invasion ability of MiaPaCa-2 cells in vitro. Ezrin
overexpression may be sufficient to confer metastatic
potential [38], and ezrin silencing may reverse metastatic
behavior, through other ways [21]. These underlying
mechanisms require further elucidation.
Immunohistochemical analysis demonstrated that ezrin
expression was elevated in PDAC samples compared to
normal pancreatic tissues, which provided additional evi-
dence supporting a functional role of ezrin in pancreatic
cancer development. We also observed that ezrin was
highly expressed in precancerous lesions, such as PanINs
(97.1%, 33/34) and tubular complexes in CP (85.7%, 24/
28). These observations have further significance. The
detection and treatment of early-stage, non-invasive
PanINs has a major impact on pancreatic cancer survival.
PanINs are morphologically classified into three grades,
according to nuclear polarity, nuclear size (pleomorph-
ism) and hyper-chromatic staining [39,40]. Despite com-
plex associations between tumor cells and PanINs,
histological and molecular evidence suggests that PanINs
can gradually progress to PDAC, bearing genetic traits
such as Ras mutations, Cyclin D1 overexpression and
loss of p16 expression [41,42]. Because CP is also an
independent risk factor for PDAC development [41],
high ezrin expression proportion in CP and PanINs sug-
gests that ezrin might be involved in the earliest stages of
PDAC pathogenesis and could potentially serve as an
indicator for those lesions progressing to the more
advanced stage–PDAC. Ezrin was also expressed in the
intercalated ducts in the pancreatic tissue that was adja-
cent to the adenocarcinoma, which was considered to be
the origin in the pancreatic ducts and acini, as well as the
starting point of PDAC development [43,44]. The results
indicate that ezrin may play an important role in the
early development of pancreatic ductal carcinoma.
In conclusion, we successfully overexpressed and
silenced the ezrin protein expression in MiaPaCa-2
cells, and found that changes in the ezrin protein level
were correlated with changes in the formation of
dynamic cell protrusions, motility, invasion and the abil-
ity of anchorage-independent growth, which are all
tumor cells features. Based on these results, we propose
that ezrin, by participating in the formation of cell pro-
trusions and the enhancement of anchorage-indepen-
dent growth ability, might promote invasion and
metastasis in carcinogenesis. These processes may be
attributed to the activation of the Erk1/2 pathway
[29,30]. The high ezrin expression proportion in CP,
PanINs and ezrin expression in intercalated duct cells
suggest that ezrin might be involved in the earliest
stages of PDAC pathogenesis and could potentially
serve as an indicator for those lesions progressing to
the more advanced stage, PDAC. These results indicate
that blocking ezrin function may represent a novel and
effective strategy for preventing pancreatic cancer pro-
gression, invasion and metastasis. In pancreatic precan-
cerous lesions, such as PanINs and chronic pancreatitis,
blocking ezrin function may have therapeutic effects
that prevent these two diseases from progressing to
pancreatic cancer.
Conclusions
We propose that ezrin might play functional roles in
modulating morphology, growth, motility and invasion
of pancreatic cancer cells, and that the Erk1/2 pathway
may be involved in these roles. Moreover, ezrin may
Table 2 Association between ezrin expression and
clinico-pathologic variables in 70 patients with
pancreatic ductal adenocarcinoma






< 65 53 47 6
> 65 17 17 0
Gender 0.34
Male 45 41 4
Female 25 23 2
Histopathogic grading 0.4688
G1 8 8 0
G2 38 34 4
G3 24 22 2
Depth of invasion 0.653
T1 2 2 0
T2 17 15 8
T3 46 42 4
T4 5 5 0
Pathologic stage 0.249
I 5 5 0
II 16 14 2
III 41 39 23
IV 8 6 2
LN metastasis 0.3304
Negative 27 25 2
Positive 43 39 4
LN:Lymph node
*Fisher’s exact test was used for analysis
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participate in the early events of PDAC development
and may promote its progression to the advanced stage.
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